COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,760 Articles (22,502 medRxiv, 8,258 bioRxiv)

Most recent first Previous |  Page 845: Articles 8441-8450  | Next

Analyzing county-wide trends in Tennessee Covid-19 rates, Median Household Income, and Presence of Hospital
Brahmbhatt, V. V.
10.1101/2022.03.02.22271656 — Posted: 2022-03-04
Estimating relative generation times and relative reproduction numbers of Omicron BA.1 and BA.2 with respect to Delta in Denmark
Ito, K., Piantham, C., Nishiura, H.
10.1101/2022.03.02.22271767 — Posted: 2022-03-04
Disparities in SARS-CoV-2 case rates by ethnicity, religion, measures of socio-economic position, English proficiency, and self-reported disability: cohort study of 39 million people in England during the Alpha and Delta waves
Larsen, T., Bosworth, M. L., Ayoubkhani, D., Schofield, R., Ali, R., Khunti, K., Walker, A. S., Glickman, M., Nafilyan, V.
10.1101/2022.03.02.22271762 — Posted: 2022-03-04
COVID-SAFER: Deprescribing Guidance for Nirmatrelvir-ritonavir Drug Interactions in Older Adults
Ross, S., Bortolussi-Courval, E., Hanula, R., Lee, T. C., Wilson, M. G., Gibson McDonald, E.
10.1101/2022.03.01.22271254 — Posted: 2022-03-04
Predictive Model of Risk Factors of High Flow Nasal Cannula Using Machine Learning in COVID-19
Matsunaga, N., Kamata, K., Asai, Y., Tsuzuki, S., Sakamoto, Y., Ijichi, S., Akiyama, T., Yu, J., Yamada, G., Terada, M., Suzuki, S., Suzuki, K., Saito, S., Hayakawa, K., Ohmagari, N.
10.1101/2022.03.02.22271673 — Posted: 2022-03-04
Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo controlled randomized trial in healthcare workers
Del Amo, J.
10.1101/2022.03.02.22271710 — Posted: 2022-03-04
NOVEL RT-qPCR ASSAYS ENABLE RAPID DETECTION AND DIFFERENTIATION BETWEEN SARS-COV-2 OMICRON (BA.1) AND BA.2 VARIANTS
ERSTER, O., Kabat, A., Asraf, H., Levy, V., Mannasse, B., Azar, R., Nemet, I., Kliker, L., Fleishon, S., Mandelboim, M., Mendelson, E., Zuckerman, N. S.
10.1101/2022.02.22.22271222 — Posted: 2022-03-04
Determining the optimal SARS-CoV-2 mRNA vaccine dosing interval for maximum immunogenicity
Asamoah-Boaheng, M., Goldfarb, D. M., Prusinkiewicz, M., Golding, L., Karim, M. E., Barakauskas, V., Wall, N., Jassem, A. N., Marquez, A. C., MacDonald, C., O'Brien, S. F., Lavoie, P., Grunau, B.
10.1101/2022.03.01.482592 — Posted: 2022-03-04
Pegylated-interferon-{lambda} treatment-induced peripheral interferon stimulated genes are associated with SARS-CoV-2 viral load decline despite delayed T cell response in older individuals
Santer, D. M., Li, D., Ghosheh, Y., Zahoor, M. A., Prajapati, D., Tyrrell, D. L. J., Feld, J. J., Gehring, A. J.
10.1101/2022.02.24.22271438 — Posted: 2022-03-03
Z-RNA and the flipside of the SARS Nsp13 helicase
Herbert, A., Shein, A., Poptsova, M.
10.1101/2022.03.03.482810 — Posted: 2022-03-03

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).